- Home
- DMLP vs NTLA Comparison
DMLP vs NTLA Comparison
Compare DMLP & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- NTLA
- Stock Information
- Founded
- DMLP 2003
- NTLA 2014
- Country
- DMLP United States
- NTLA United States
- Employees
- DMLP N/A
- NTLA N/A
- Industry
- DMLP Oil & Gas Production
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DMLP Energy
- NTLA Health Care
- Exchange
- DMLP Nasdaq
- NTLA Nasdaq
- Market Cap
- DMLP 1.3B
- NTLA 1.2B
- IPO Year
- DMLP N/A
- NTLA 2016
- Fundamental
- Price
- DMLP $27.75
- NTLA $12.33
- Analyst Decision
- DMLP
- NTLA Buy
- Analyst Count
- DMLP 0
- NTLA 19
- Target Price
- DMLP N/A
- NTLA $35.11
- AVG Volume (30 Days)
- DMLP 65.4K
- NTLA 4.6M
- Earning Date
- DMLP 08-08-2025
- NTLA 08-11-2025
- Dividend Yield
- DMLP 11.66%
- NTLA N/A
- EPS Growth
- DMLP N/A
- NTLA N/A
- EPS
- DMLP 2.03
- NTLA N/A
- Revenue
- DMLP $166,824,000.00
- NTLA $45,569,000.00
- Revenue This Year
- DMLP N/A
- NTLA N/A
- Revenue Next Year
- DMLP N/A
- NTLA N/A
- P/E Ratio
- DMLP $13.80
- NTLA N/A
- Revenue Growth
- DMLP 12.09
- NTLA N/A
- 52 Week Low
- DMLP $25.84
- NTLA $5.90
- 52 Week High
- DMLP $34.88
- NTLA $27.28
- Technical
- Relative Strength Index (RSI)
- DMLP 52.34
- NTLA 55.16
- Support Level
- DMLP $27.10
- NTLA $12.48
- Resistance Level
- DMLP $28.00
- NTLA $13.73
- Average True Range (ATR)
- DMLP 0.39
- NTLA 0.91
- MACD
- DMLP 0.05
- NTLA -0.08
- Stochastic Oscillator
- DMLP 72.22
- NTLA 31.74
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.